Deborah Siegal/LinkedIn
Mar 1, 2026, 10:31
Deborah Siegal Explores ARTESiA in The CLOT Conversation’s Latest Episode
Thrombosis Canada shared on LinkedIn:
”Major bleeding remains the leading complication of oral anticoagulation.
In our latest episode of CLOT Conversations, Dr. Deborah Siegal discusses the ARTESiA subanalysis examining major bleeding with apixaban versus aspirin in patients with device-detected subclinical atrial fibrillation.
Key insights:
- Apixaban reduced stroke/systemic embolism by 37%
- Major bleeding increased, largely driven by gastrointestinal events
- Intracranial and fatal bleeding rates were low and similar
- Most bleeding events were not clinical emergencies
- NSAID use emerged as a key modifiable risk factor
Understanding not just how often bleeding occurs, but how severe it is, is critical to individualized risk assessment and shared decision-making.”
Stay updated with Hemostasis Today.
-
Mar 1, 2026, 09:46Jecko Thachil: Tackling the Balance Between Bleeding and Thrombosis in CKD
-
Mar 1, 2026, 09:35Emmanuel J Favaloro: When Tallied Together, Rare Bleeding Disorders Are Not So Rare
-
Mar 1, 2026, 09:10Satyam Arora: A Key Gap In Standardized Protocols for Pediatric Massive Transfusion
-
Mar 1, 2026, 08:46Heghine Khachatryan: The Future of Anticoagulation Beyond DOACs
-
Mar 1, 2026, 05:44Ilenia Calcaterra: Innovation In Rare Diseases Is Never Abstract
-
Feb 28, 2026, 17:03Investing in Education, Prevention, and Lifesaving Research for a Healthier Tomorrow – AHA
-
Feb 28, 2026, 17:00Pamela Gavin: 1 in 10 Americans Live With A Rare Disease – That Is Not Rare, That Is Public Health
-
Feb 28, 2026, 16:59Thomas Rocco Jr: Exploring Agentic AI in Cardiovascular Medicine
-
Feb 28, 2026, 16:50Rob Maloney: Normalcy Is Not A Small Thing In Rare Disease